Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
CYCN
globenewswire.comDecember 17, 2024
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
CYCN
globenewswire.comAugust 7, 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.